Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Revance The stock (RVNC)

Buy Revance The stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Revance The is a biotechnology business based in the US. Revance The shares (RVNC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.70 – a decrease of 10.98% over the previous week. Revance The employs 597 staff and has a trailing 12-month revenue of around $251.2 million.

Our top picks for where to buy Revance The stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

How to buy Revance The stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – RVNC. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Revance The stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Revance The stock price (NASDAQ: RVNC)

Use our graph to track the performance of RVNC stocks over time.

Revance The shares at a glance

Information last updated 2024-10-24.
Latest market close$4.70
52-week range$2.30 - $9.75
50-day moving average $5.89
200-day moving average $4.70
Wall St. target price$8.95
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-3.43

Is it a good time to buy Revance The stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Revance The price performance over time

Historical closes compared with the close of $4.7 from 2024-10-25

1 week (2024-10-21) -10.98%
1 month (2024-09-27) -12.31%
3 months (2024-07-26) 19.90%
6 months (2024-04-26) 38.24%
1 year (2023-10-27) -41.10%
2 years (2022-10-28) -79.06%
3 years (2021-10-28) 13.76
5 years (2019-10-28) 15.25

Revance The financials

Revenue TTM $251.2 million
Gross profit TTM $-20,388,000
Return on assets TTM -22.77%
Return on equity TTM -2096.78%
Profit margin -114.46%
Book value $-1.24
Market Capitalization $552.2 million

TTM: trailing 12 months

Revance The share dividends

We're not expecting Revance The to pay a dividend over the next 12 months.

Revance The share price volatility

Over the last 12 months, Revance The's shares have ranged in value from as little as $2.3 up to $9.745. A popular way to gauge a stock's volatility is its "beta".

RVNC.US volatility(beta: 0.98)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Revance The's is 0.982. This would suggest that Revance The's shares are less volatile than average (for this exchange).

Revance The overview

Revance Therapeutics, Inc. , a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA.

Frequently asked questions

What percentage of Revance The is owned by insiders or institutions?
Currently 8.578% of Revance The shares are held by insiders and 75.04% by institutions.
How many people work for Revance The?
Latest data suggests 597 work at Revance The.
When does the fiscal year end for Revance The?
Revance The's fiscal year ends in December.
Where is Revance The based?
Revance The's address is: 1222 Demonbreun Street, Nashville, TN, United States, 37203
What is Revance The's ISIN number?
Revance The's international securities identification number is: US7613301099
What is Revance The's CUSIP number?
Revance The's Committee on Uniform Securities Identification Procedures number is: 761330109

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site